FONTEYNE PAUL R. — SEC Form 4 filings
SEC reporting owner CIK 1727550. 7 Form 4 filings on record with FilingPulse; latest filed 2026-08-03.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-06-07 to 2026-08-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | Director | 3 | — | — | 17 |
| Apnimed, Inc. (APMD) | Director | 1 | — | — | 7 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | Director | 3 | — | — | 3 |
Form 4 filings — FONTEYNE PAUL R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-03 | 4 | Apnimed, Inc. (APMD) | Disposition to issuer (D): 51,890 (derivative) @ $0 · Grant/award (A): 51,890 (derivative) @ $0 · Disposition to issuer (D): 44,477 (derivative) @ $0 · Grant/award (A): 44,477 (derivative) @ $0 · Grant/award (A): 44,477 (derivative) @ $0 · Disposition to issuer (D): 44,477 (derivative) @ $0 · +1 more | EDGAR |
| 2026-06-08 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 24,372 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Code (U): 30,666 · Disposition to issuer (D): 3,062 · Disposition to issuer (D): 5,744 · Disposition to issuer (D): 7,961 · Disposition to issuer (D): 3,544 · Disposition to issuer (D): 3,877 · +7 more | EDGAR |
| 2026-01-05 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 7,961 @ $0 · Grant/award (A): 14,684 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | Apellis Pharmaceuticals, Inc. (APLS) | Grant/award (A): 6,267 @ $0 · Grant/award (A): 11,199 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Amylyx Pharmaceuticals, Inc. (AMLX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1727550 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →